GlycoBAR is excited to announce the successful completion of our latest fundraising round, enabling us to finalize the scale-up of our production. We are now poised to deliver our innovative blood group antigen ligands at high volumes and low costs. For the first time ever, it will be possible and economically viable to remove blood group antibodies from plasma and plasma derivative products. Our technology also transforms highly perishable, group-specific platelet-rich plasma into universal (blood group-independent) products, promising significant cost savings for hospitals. We extend our heartfelt thanks to our new investors—Iron Hands Capital, Rhône Dauphiné Développement (RDD), Good Only Ventures, and the numerous business angels who have supported us through a joint holding. Your support, along with that of our customers and prospective customers, is invaluable. Stay tuned for more exciting updates!
GlycoBAR
Recherche en biotechnologie
Domène, Auvergne-Rhône-Alpes 35 abonnés
GlycoBAR: a new and cost effective way to get rid for blood group antibodies. No blood group barrier any more !
À propos
GlycoBAR sells blood group antigen ligands that can be used to make plasma "Universal" (=compatible with all recipients, whichever the blood group of the donor is). Our ligands are also allowing transplant of organs when donor and recipients are belonging to incompatible blood group
- Site web
-
www.glycobar.com
Lien externe pour GlycoBAR
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Domène, Auvergne-Rhône-Alpes
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2015
- Domaines
- Biofermentation, Blood purification, Blood group antibody removal et Isoagglutinins removal
Lieux
-
Principal
Obtenir l’itinéraire
19, Rue Casimir Julhiet
Espace Colombiers
38420 Domène, Auvergne-Rhône-Alpes, FR